Eli Lilly's Omvoh Delivers 50 Percent Clinical Remission at One Year in Pediatric Ulcerative Colitis Trial

Eli Lilly has disclosed late-stage study outcomes showing that half of young patients who responded to initial therapy with Omvoh reached complete clinical remission after a full year.¹ This result satisfies the designated primary endpoint of the Phase 3 SHINE-2 trial, which evaluated the therapeutic agent in pediatric patients managing moderately to severely active ulcerative colitis.¹ The achievement marks a developmental milestone across the broader pharmaceutical field, establishing Omvoh as the initial IL-23p19 inhibitor to deliver one-year Phase 3 trial results in pediatric ulcerative colitis.¹ The newly reported data confirm that the drug can sustain therapeutic benefits over extended periods in younger patient populations who face chronic inflammatory bowel disorders.¹

The long-term success observed at the 52-week mark built upon substantial gains documented during the earlier induction stage of the program.¹ Investigators reported that 81% of pediatric patients with moderately to severely active ulcerative colitis achieved a clinical response after 12 weeks of Omvoh induction.¹ Patients demonstrating positive responses during those first three months were then followed through the continuation phase to measure whether clinical improvements could be preserved.¹ By Week 52, exactly 50% of those induction responders had achieved formal clinical remission under the SHINE-2 protocol.¹

Secondary evaluations demonstrated that the clinical benefits extended beyond the primary remission threshold to encompass critical structural and symptom-based improvements.¹ Among the cohort responding to induction, half of the patients attained corticosteroid-free clinical remission without surgical intervention at one year.¹ Daily physical burdens also lessened considerably, with 71.2% of responders reaching symptomatic remission at the one-year mark of the SHINE-2 trial.¹ Direct tissue evaluation confirmed objective healing inside the bowel wall, as endoscopic improvement was documented in 53.8% of responders at Week 52 in the trial.¹

These trial milestones were recorded across a participant pool that entered the evaluation facing high levels of disease complexity and limited therapeutic alternatives.¹ Fifty percent of patients entered the trial with severe disease activity as evaluated by the Pediatric Ulcerative Colitis Activity Index.¹ In addition, more than half of the pediatric patients enrolled in the SHINE-2 trial had previously failed biologic treatments.¹ The efficacy observed at Week 52 was therefore achieved within a group that had already demonstrated resistance to established biological therapies and displayed substantial baseline illness.¹

Addressing juvenile inflammation is an urgent clinical focus in the United States, where ulcerative colitis affects over 26,000 children and adolescents.¹ Throughout the trial, safety monitoring tracked how young participants tolerated continuous administration over 52 weeks of care.¹ Four pediatric patients, representing 6.3% of the study group, experienced a serious adverse event through Week 52, none of which were deemed related to Omvoh.¹ Over the same annual evaluation span, treatment discontinuation occurred in two pediatric patients due to a flare of ulcerative colitis.¹

The pediatric findings expand an already broad global commercial and regulatory foundation that Eli Lilly has established for the therapy in mature patient groups.¹ Omvoh has received adult treatment approvals for moderately to severely active ulcerative colitis and Crohn's disease across 47 countries.¹ Securing Phase 3 validation for children and adolescents enables the company to prepare regulatory filings aimed at widening its prescribing label beyond those adult clearances.¹ The clinical progression positions the therapy as an emerging long-term maintenance option in pediatric gastroenterology worldwide.¹

Beyond its gastrointestinal immunology portfolio, Eli Lilly is also securing key regulatory milestones across its metabolic health developments.² In Europe, an EMA committee recommended granting marketing authorization for Eli Lilly's oral obesity drug Foundayo for weight management and adult type 2 diabetes.² With that regulatory endorsement, Foundayo is the second oral obesity medication to secure a positive backing from the European Medicines Agency committee, coming after Novo Nordisk's Wegovy pill.² The regulatory progress strengthens Lilly's international presence in chronic metabolic disease care.²

Foundayo functions through a distinct biochemical approach designed for daily oral ingestion rather than injection.² Specifically, Foundayo contains the small-molecule GLP-1 receptor agonist orforglipron, which helps suppress appetite and reduce food consumption.² Commercial rollouts have already commenced, and Foundayo produced $98 million in sales during the second quarter following rollouts in the United States and the United Kingdom.² In the same reporting period, Novo Nordisk's oral formulation of Wegovy generated 3.22 billion Danish crowns, or $484.50 million, in second-quarter sales.²

Financial stakes in the weight-loss sector are climbing rapidly as pharmaceutical makers expand their non-injectable options.² Industry projections anticipate the oral obesity drug market will exceed $100 billion by 2030.² Eli Lilly is also advancing next-generation injectable alternatives, most notably retatrutide, which combines agonism of glucagon receptors with GLP-1 and GIP receptor activity.³ Clinical results indicate that over a two-year span, retatrutide can enable patients to shed approximately 28 percent of their body weight.³

Eli Lilly is approaching the end of Phase 3 testing for retatrutide before submitting the candidate to the FDA for regulatory review.³ Throughout the candidate's clinical assessments, safety patterns have mirrored other potent gut hormone therapies.³ Gastrointestinal symptoms represent the most frequent adverse events observed in leading clinical trials for retatrutide.³ Evidence supports that Eli Lilly is concurrently pursuing multiple clinical and regulatory strategies in the incretin-based metabolic sector through both small-molecule oral pills and multi-receptor injectable peptides.²